A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease.
暂无分享,去创建一个
R. Tsang | M. Pintilie | M. Crump | R. Meyer | E. Yu | J. Sussman | S. Myrehaug | D. Hodgson | L. Yun
[1] J. Lubin,et al. Coronary artery disease mortality in patients treated for hodgkin's disease , 2010, Cancer.
[2] L. Specht,et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review , 2010, Haematologica.
[3] S. Fosså,et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study , 2009, British Journal of Cancer.
[4] F. Stewart,et al. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. , 2008, International journal of radiation oncology, biology, physics.
[5] F. Stewart,et al. Radiation-induced cardiovascular injury , 2008, Radiation and environmental biophysics.
[6] R. Tsang,et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy , 2008, Leukemia & lymphoma.
[7] A. Hart,et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.
[8] A. Horwich,et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.
[9] F. Stewart,et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. , 2006, The American journal of pathology.
[10] C. Pepine,et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.
[11] S. Hancock,et al. Asymptomatic cardiac disease following mediastinal irradiation. , 2003, Journal of the American College of Cardiology.
[12] W. Mackillop,et al. Evolution of treatment for Hodgkin's disease: a population-based study of radiation therapy use and outcome. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).
[13] Z. Qian,et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. , 2001, Life sciences.
[14] V. Diehl,et al. Hodgkin disease: prognostic factors and treatment strategies , 2000, Current opinion in oncology.
[15] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[16] P. Levendag,et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] S L Hancock,et al. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.
[18] A. Allen,et al. The cardiotoxicity of chemotherapeutic drugs. , 1992, Seminars in oncology.
[19] A. Buzdar,et al. Early and delayed clinical cardiotoxicity of doxorubicin , 1985, Cancer.
[20] J. Boivin,et al. Coronary heart disease mortality after irradiation for Hodgkin's disease , 1982, Cancer.
[21] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[22] P. Kaufmann,et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] P. Rubin,et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. , 1996, International journal of radiation oncology, biology, physics.
[24] P. Dawes,et al. Malignant melanoma of the external auditory meatus. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).